Evolution in disease severity during the E-cigarette or Vaping-Associated Lung Injury (EVALI) outbreak

M. Lanspa (Salt Lake City, United States of America), D. Harris (Salt Lake City, United States of America), B. Anderson (Parker, United States of America), S. Callahan (Salt Lake City, United States of America), S. Rea (Salt Lake City, United States of America), D. Collingridge (Salt Lake City, United States of America), D. Guidry (Salt Lake City, United States of America), C. Grissom (Salt Lake City, United States of America), D. Blagev (Salt Lake City, United States of America)

Source: Virtual Congress 2020 – From tobacco and vaping health effects to tobacco cessation
Session: From tobacco and vaping health effects to tobacco cessation
Session type: Oral Presentation
Number: 4388
Disease area: Respiratory critical care

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Lanspa (Salt Lake City, United States of America), D. Harris (Salt Lake City, United States of America), B. Anderson (Parker, United States of America), S. Callahan (Salt Lake City, United States of America), S. Rea (Salt Lake City, United States of America), D. Collingridge (Salt Lake City, United States of America), D. Guidry (Salt Lake City, United States of America), C. Grissom (Salt Lake City, United States of America), D. Blagev (Salt Lake City, United States of America). Evolution in disease severity during the E-cigarette or Vaping-Associated Lung Injury (EVALI) outbreak. 4388

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Chemical injury: Reality or myth?
Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice
Year: 2015


Fibrosis in emphysema: Radiologically occult but histologically prevalent process proportionate to smoking burden
Source: International Congress 2014 – ILDs 6
Year: 2014

Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used
Source: International Congress 2017 – Rare diseases
Year: 2017

LATE-BREAKING ABSTRACT: Burden and risk factors of chronic bronchitis - results from the Burden of Obstructive Lung Disease (BOLD) Study
Source: International Congress 2014 – Epidemiology of asthma
Year: 2014


LSC 2014 abstract - Influenza infection may cause exacerbation of lung fibrosis through collagen deposition
Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells
Year: 2014

Lung cancer in never smokers. An update of the Lung Cancer Risk Factors in Never Smokers Study (LCRINS)
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017


Physical activity and symptom burden in COPD: The Canadian Cohort Obstructive Lung Disease (CanCOLD) study
Source: Virtual Congress 2021 – Lung disease burden and management
Year: 2021


Essential oils reduced lung inflammation in a model of acute lung injury
Source: International Congress 2014 – Experimental models in acute lung injury
Year: 2014

Estimating Chronic Respiratory Disease (Asthma and COPD) burden in adults in Asian LMICs: a pilot study for 4CCORD [4 Country ChrOnic Respiratory Disease study].
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020


Symptoms of chronic bronchitis are associated with lower heart rate variability - SAPALDIA 2 - Swiss Cohort Study on Air Pollution and Lung diseases in Adults
Source: Eur Respir J 2005; 26: Suppl. 49, 120s
Year: 2005

Lung inflammation was attenuated by sakuranetin treatment in a model of acute lung injury
Source: International Congress 2014 – Experimental models in acute lung injury
Year: 2014

Outcome of acute drug-induced pneumonias in ICU
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013


Biomarkers of asthma severity in the gene environment interaction in respiratory disease (GEIRD) study
Source: International Congress 2014 – Lung function, COPD and inflammation
Year: 2014

Late Breaking Abstract - Characteristics of T2-biomarker low severe asthma patients in the UK Severe Asthma Registry (UKSAR)
Source: International Congress 2019 – Asthma epidemiology in the 21st century
Year: 2019

LATE-BREAKING ABSTRACT: Trasplantation of alveolar type II cells in experimental Acute Lung Injury
Source: International Congress 2014 – Lung cell biology in injury and repair
Year: 2014

Late Breaking Abstract - Assessment of disease progression in IPF patients using Functional Respiratory Imaging (FRI)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems
Year: 2017



Increase in hospital admissions in smokers with Interstitial Lung Abnormalities in the Danish Lung Cancer Screening Trial (DLCST)
Source: International Congress 2018 – COPD and chronic respiratory disease: from misclassification to radiological findings
Year: 2018



Risk factors of near fatal asthma: the Lung Center of the Philippines experience
Source: Eur Respir J 2006; 28: Suppl. 50, 614s
Year: 2006

COPD prevalence in Portugal. The Burden of Obstructive Lung Disease study (BOLD)
Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD
Year: 2010


Pathology of Vaping-Associated Lung Injury
Source: Virtual Congress 2020 – E-cigarette or Vaping, product use Associated Lung Injury (EVALI)
Year: 2020